[Summary] An innovative biopharmaceutical company focused on disease treatment a
Bioheng is a clinical-stage company focused on the development and clinical translation of allogeneic "off-the-shelf" universal CAR-T therapies. Founded in 2017, the company aims to develop a "world-leading" allogeneic cell therapy platform and products to address challenging and unmet clinical needs.
In March 2022, Bioheng's CTA101 universal CAR-T cell therapy received Investigational New Drug (IND) approval.
In June 2021, Bioheng's CD7-targeted universal CAR-T cell therapy received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). This product is based on Bioheng's independently developed universal CAR-T technology platform, ANSWER®. The company is advancing global clinical trials of this promising product pipeline.
Based on the ANSWER® platform, Bioheng is actively developing multiple universal CAR-T product pipelines. These programs have demonstrated strong and durable allogeneic CAR-T cell persistence, showing strong potential in autoimmune and oncology fields.
We are always making our utmost efforts to fill unmet clinical needs.
Company website: *
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows